4-HO-DiPT
 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Duration of action | 2–3 hours[1] |
| Identifiers | |
| |
| CAS Number |
|
| ChemSpider | |
| UNII |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.214.853 |
| Chemical and physical data | |
| Formula | C16H24N2O |
| Molar mass | 260.381 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
4-HO-DiPT, also known as 4-hydroxy-N,N-diisopropyltryptamine or as iprocin, is a synthetic psychedelic drug of the tryptamine family. It is a higher homologue of psilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT.
Dosage
[edit]In TiHKAL, Alexander Shulgin reported that 4-HO-DiPT had a dose range of 15 to 20 mg orally and a duration of 2 to 3 hours.[1] However, a wider recreational dose range of 3 to 30 mg or more orally has also been reported.[2] The drug is active at around 3 mg and above, and its effects last for 2 to 3 hours.[3] Higher doses, such as those above 30 mg, can increase the duration of its effects significantly.
Effects
[edit]The effects of 4-HO-DiPT are broadly comparable to those of other serotonergic psychedelics such as LSD and psilocin, but they are distinguished by their relative brevity. Shulgin "doubt[s] that there is another psychedelic drug, anywhere, that can match this one for speed, for intensity, for brevity, and sensitivity to dose, at least one that is active orally." An idiosyncratic effect of the drug, also noted by Shulgin, is its tendency to induce tremors.[1][4][5]
Some users have reported a minor audio distortion with lower dosages. Higher dosages increase the polarity of the distortion. It is defined as being slightly lower in pitch and creating several different effects, such as pitch bend, volume distortion, and rate distortion. As with most DiPT psychedelics, music can become more dissonant and less harmonious. Users have also reported a visual distortion widely comparable to the hallucinogen LSD.
Interactions
[edit]Pharmacology
[edit]Pharmacodynamics
[edit]| Binding Sites | Binding Affinity Ki (μM) | Action [6] |
|---|---|---|
| 5-HT1A | 5.7 | ??? |
| 5-HT2A | 0.728 | partial agonist |
| 5-HT2C | 2.8 | ??? |
| D1 | >25 | ??? |
| D2 | >25 | ??? |
| D3 | >25 | ??? |
| α1A | >12 | ??? |
| α2A | 15 | ??? |
| TAAR1 | >15 | ??? |
| H1 | 9.8 | ??? |
| SERT | 1.8 | inhibitor |
| DAT | >26 | inhibitor |
| NET | 11 | inhibitor |
Legal status
[edit]Finland
[edit]Scheduled in government decree on psychoactive substances banned from the consumer market.[7]
Germany
[edit]Scheduled in New Psychoactive Substances Act (NpSG). Use of covered substances is permitted only for industrial and scientific purposes.
Sweden
[edit]Sveriges riksdags health ministry Statens folkhälsoinstitut classified 4-HO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Mar 1, 2005, in their regulation SFS 2005:26 listed as 4-hydroxi-N,N-diisopropyltryptamin (4-HO-DIPT), making it illegal to sell or possess.[8]
United States
[edit]4-HO-DiPT is not scheduled at the federal level in the United States,[9] but it is possible that it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
Florida
[edit]"4-Hydroxy-N,N-diisopropyltryptamine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[10]
Research
[edit]
FT-104 (O-glutaryl-4-HO-DiPT), a prodrug to 4-HO-DiPT, has entered double blind, randomized, placebo controlled, phase 1 clinical trials in healthy volunteers at the Royal Adelaide Hospital in Australia for the treatment of postpartum depression and treatment-resistant depression. [11][12][13]
References
[edit]- ^ a b c Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- ^ Luethi D, Liechti ME (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol. 21 (10): 926–931. doi:10.1093/ijnp/pyy047. PMC 6165951. PMID 29850881.
- ^ "Erowid 4-HO-DiPT Vault : Dosage". www.erowid.org. Retrieved 8 April 2023.
- ^ "4-Hydroxy-DIPT". Erowid.
- ^ "Tihkal 4-HO-DIPT entry".
- ^ Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). European Neuropsychopharmacology. 26 (8): 1327–37. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487. S2CID 6685927.
- ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 1130/2014". www.finlex.fi. Retrieved 8 April 2023.
- ^ "Svensk författningssamling" [Swedish Code of Statutes] (PDF) (in Swedish). Archived from the original (PDF) on 29 September 2013. Retrieved 25 September 2013.
- ^ "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I." Archived from the original on 27 August 2009. Retrieved 17 December 2014.
- ^ "Statutes & Constitution :View Statutes : Online Sunshine". leg.state.fl.us. Retrieved 8 April 2023.
- ^ "Field Trip Announces First Dosings in Phase I Clinical Study of FT-104" (Press release). 21 July 2022.
- ^ "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104". 11 August 2022.
- ^ "WIPO - Search International and National Patent Collections". patentscope.wipo.int. Retrieved 8 April 2023.